Loading...
XSHE002294
Market cap4.86bUSD
Dec 26, Last price  
31.87CNY
1D
-1.39%
1Q
1.18%
Jan 2017
8.82%
IPO
40.61%
Name

Shenzhen Salubris Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XSHE:002294 chart
P/E
61.25
P/S
10.56
EPS
0.52
Div Yield, %
1.54%
Shrs. gr., 5y
1.24%
Rev. gr., 5y
-6.27%
Revenues
3.37b
-3.35%
203,143,936349,434,747527,169,507849,597,6711,297,767,1161,474,884,5261,828,881,5332,327,483,5052,882,644,6043,477,692,8683,833,490,2234,153,776,6094,651,876,1994,470,465,9802,738,562,2963,058,392,0413,482,011,3783,365,343,342
Net income
580m
-8.95%
34,238,76973,137,727116,941,762215,747,086355,314,294405,249,376635,167,523830,416,5811,042,297,0821,265,920,0251,396,414,1501,451,887,2581,458,223,270715,201,07660,864,986533,726,576637,091,085580,066,240
CFO
870m
-10.41%
12,004,69552,753,54377,893,191134,282,021186,649,350272,318,579521,213,683668,521,964982,249,1461,056,028,8261,434,812,0031,457,722,4261,340,663,5161,506,644,7991,374,329,0191,184,978,525970,804,863869,792,266
Dividend
Jun 19, 20240.5 CNY/sh

Profile

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel bisulfate tablets, as well as bivalirudin and pamidronate disodium injections; recombinant SeV-hFGF2/dF Injection for the treatment of diabetic foot disease; and anti-tumor and orthopedics medicines. The company also provides anti-infection products comprising cefonicid sodium, ceftazidime, ceftriaxone sodium, cefonicid sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium injections, as well as azithromycin dispersible and levetiracetam tablets. In addition, it offers biotechnological drugs, such as recombinant protein and monoclonal antibody drugs. Further, the company is involved in import, licensing-in, and licensing-out medicines for Europe markets. The company was founded in 1998 and is headquartered in Shenzhen, China.
URL
http://www.salubris.cn/
IPO date
Sep 10, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,365,343
-3.35%
3,482,011
13.85%
3,058,392
11.68%
Cost of revenue
2,151,327
2,684,159
2,247,252
Unusual Expense (Income)
NOPBT
1,214,016
797,852
811,140
NOPBT Margin
36.07%
22.91%
26.52%
Operating Taxes
60,932
79,507
71,520
Tax Rate
5.02%
9.97%
8.82%
NOPAT
1,153,084
718,345
739,620
Net income
580,066
-8.95%
637,091
19.37%
533,727
776.90%
Dividends
(545,680)
(437,564)
(1,600)
Dividend yield
1.50%
1.21%
0.01%
Proceeds from repurchase of equity
26,195
64,492
BB yield
-0.07%
-0.22%
Debt
Debt current
40,000
188,651
69,985
Long-term debt
25,077
39,165
18,225
Deferred revenue
84,114
98,535
93,714
Other long-term liabilities
416,474
29,641
82,573
Net debt
(3,839,098)
(3,166,797)
(3,849,483)
Cash flow
Cash from operating activities
869,792
970,805
1,184,979
CAPEX
(670,999)
Cash from investing activities
(1,401,139)
Cash from financing activities
(705,535)
1,548,328
FCF
1,154,072
717,677
709,835
Balance
Cash
2,203,541
2,998,829
3,295,871
Long term investments
1,700,634
395,784
641,822
Excess cash
3,735,908
3,220,512
3,784,773
Stockholders' equity
6,823,410
6,744,581
6,443,192
Invested Capital
4,872,645
5,023,565
4,453,276
ROIC
23.30%
15.16%
16.50%
ROCE
14.08%
9.65%
9.85%
EV
Common stock shares outstanding
1,115,512
1,098,433
1,067,453
Price
32.66
-0.58%
32.85
20.24%
27.32
-3.57%
Market cap
36,432,622
0.97%
36,083,521
23.73%
29,162,820
0.09%
EV
32,629,957
32,952,536
25,325,247
EBITDA
1,559,622
1,118,010
1,115,408
EV/EBITDA
20.92
29.47
22.70
Interest
17,373
12,539
10,527
Interest/NOPBT
1.43%
1.57%
1.30%